Related Experiment Video
Updated: Aug 26, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Biomarkers associated with coronary high-risk plaques
Akihiro Nakajima1,2, Peter Libby3, Satoru Mitomo2
1Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRB 800, Boston, MA, 02114, USA.
Insights
This study identifies key blood biomarkers for detecting high-risk coronary plaques, including thin-cap fibroatheroma (TCFA). These findings aid in patient risk stratification and targeted therapy development for cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Atherosclerosis Research
Background:
- Vascular inflammation, lipid metabolism, and thrombogenicity are crucial in atherogenesis and acute coronary syndromes.
- Identifying biomarkers for high-risk coronary plaques, particularly those defined by intravascular imaging, remains an unmet clinical need.
Purpose of the Study:
- To systematically investigate comprehensive biomarkers associated with coronary high-risk plaques, including thin-cap fibroatheroma (TCFA).
- To develop and validate composite biomarker models for accurate detection of TCFA and high-risk plaques.
Main Methods:
- Analysis of comprehensive inflammation, lipid, and coagulation biomarkers in 69 patients with coronary artery disease.
- Utilized optical coherence tomography (OCT) and intravascular ultrasound (IVUS) imaging to define plaque characteristics.
- Developed and validated two composite biomarker models for TCFA and high-risk plaques using logistic regression and AUC analysis.
Main Results:
- Elevated levels of high-sensitivity C-reactive protein (hsCRP), plasminogen activator inhibitor-1 (PAI-1), fibrinogen, IL-6, homocysteine, and amyloid A, along with decreased high-density lipoprotein cholesterol (HDL) and bile acid, were associated with TCFA.
- Composite models demonstrated high accuracy in detecting TCFA (AUC: 0.883-0.875) and high-risk plaques (AUC: 0.925-0.947).
- Creatinine, tumor necrosis factor-α (TNFα), and prothrombin were also identified as useful biomarkers for high-risk plaques.
Conclusions:
- Specific combinations of biomarkers have been identified as highly effective in detecting patients with TCFA and high-risk coronary plaques.
- These identified biomarkers hold potential for improving risk stratification strategies in patients with coronary artery disease.
- The findings may facilitate the development of targeted therapeutic interventions for individuals with vulnerable coronary plaques.
Abstract:
Vascular inflammation, lipid metabolism, and thrombogenicity play a key role not only in atherogenesis but also in the development of acute coronary syndromes. Biomarkers associated with coronary high-risk plaques defined according to intravascular imaging have not been systematically studied. A total of 69 patients with coronary artery disease who underwent both optical coherence tomography and intravascular ultrasound imaging, and who provided blood specimens were included. Comprehensive biomarkers for inflammation, lipid, and coagulation were analyzed. Composite models sought biomarker patterns associated with thin-cap fibroatheroma (TCFA) and "high-risk plaques" (TCFA and large plaque burden). Two different composite models were developed for TCFA, based on the finding that high sensitivity C-reactive protein (hsCRP), plasminogen activator inhibitor-1, fibrinogen, IL-6, homocysteine and amyloid A levels were elevated, and high-density lipoprotein cholesterol (HDL) and bile acid levels were decreased in these patients. Both composite models were highly accurate for detecting patients with TCFA (area under curve [AUC]: 0.883 in model-A and 0.875 in model-B, both p < 0.001). In addition, creatinine, hsCRP, fibrinogen, tumor necrosis factor-α, IL-6, homocysteine, amyloid A, HDL, prothrombin, and bile acid were useful for detecting patients with "high-risk plaques". Two composite models were highly accurate for detection of patients with "high-risk plaques" (AUC: 0.925 in model-A and 0.947 in model-B, both p < 0.001). Biomarkers useful for detection of patients with high-risk coronary plaques defined according to intravascular imaging have been identified. These biomarkers may be useful to risk stratify patients and to develop targeted therapy.Clinical Trial Registration https://www.umin.ac.jp/ctr/ , UMIN000041692. Biomarkers and high-risk plaques hsCRP, PAI-1, fibrinogen, IL-6, homocysteine, amyloid A, HDL, and bile acid were useful for detecting patients with TCFA. hsCRP, fibrinogen, IL-6, homocysteine, amyloid A, creatinine, TNFα, HDL, prothrombin, and bile acid were useful for detecting patients with "high-risk plaques" (plaque which has both TCFA and large plaque burden). White arrowhead denotes TCFA. Red and green dashed lines denote lumen area and external elastic membrane area, respectively.
More Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
07:20Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease II: Pathophysiology